EUCTR2009-017905-13-IT进行中（未招募）1 期
A randomized, 3 arm, multicentre, phase III study to evaluate the efficacy and the safety of T-DM1 combined with pertuzumab or T-DM1 combined with pertuzumab-placebo (blinded for pertuzumab), versus the combination of trastuzumab plus taxane, as first line treatment in HER2- positive progressive or recurrent locally advanced or metastatic breast cancer (MBC). - ND
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,095
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •a) Disease specific inclusion criteria: 1. HER2-positive breast cancer as defined by IHC 3+ and /or ISH positive, prospectively confirmed by a Sponsor designated central laboratory prior to enrollment. Archival tumor samples obtained from primary or metastatic sites are acceptable. 2. Histologically or cytologically confirmed adenocarcinoma of the breast with locally recurrent or metastatic disease, and be a candidate for chemotherapy. Patients with locally advanced disease must have recurrent or progressive disease, which must not be amenable to resection with curative intent.Patients with standard curative options available to them will be excluded from the trial. 3. Patients may have measurable and/or non-measurable disease which must be evaluable per RECIST 1.1. b) General inclusion criteria: 4. Signed written informed consent approved by the institution’s Independent Ethical Committee (IEC). 5. Age = 18 years. 6. ECOG Performance Status 0 or 1. 7. Adequate organ function as determined by the following laboratory results, within approximately 14 days prior to randomization: • Absolute neutrophil count > 1500 cells/mm3 • Platelet count > 100,000 cells/mm3 • Hemoglobin > 9.0 g/dL; patients may receive red blood cell transfusions to obtain this level • Total bilirubin = 1.5x upper limit of normal (ULN) unless the patient has documented Gilbert’s syndrome • SGOT (AST), SGPT (ALT), and alkaline phosphatase = 2.5 x ULN, except for patients with bone metastases: alkaline phosphatase = 5 x ULN • Serum creatinine = 1.5x upper limit of normal (ULN) • International normalized ratio (INR) and activated partial thromboplastin time (aPTT) < 1.5 x ULN (unless on therapeutic anti-coagulation) 8. For women of childbearing potential and men with partners of childbearing potential, agreement to use one highly effective form of non-hormonal contraception or two effective forms of non-hormonal contraception by the patient and/or partner and to continue its use for the duration of study treatment and for 6 months after the last dose of study treatment. Male patients whose partners are pregnant must use condoms for the duration of the study treatment and for 6 months after the last dose of study treatment. Specific country and/or local requirements for contraception will be followed. 9. A negative pregnancy test must be available for premenopausal women and for women less than 12 months after the onset of menopause.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Disease related Exclusion Criteria:
- •History of systemic anti-cancer therapy after the diagnosis of
- •MBC cancer.
- •1. An interval of < 6 months from the last dose of vincaalkaloid or taxane cytotoxic chemotherapy in the neoadjuvant or adjuvant setting until the time of metastatic diagnosis.
- •2. Hormone therapy < 7 days prior to randomization.
- •3. Trastuzumab (neoadjuvant/adjuvant setting) < 21 days prior to randomization.
- •4. Prior T-DM1 or pertuzumab therapy.
- •5. Treatment with any anti-cancer investigational drug within
- •28 days prior to commencing study treatment.
- •6. History of other malignancy within the last 5 years except for
- •appropriately treated carcinoma in situ of the cervix, nonmelanoma
- •skin carcinoma, Stage I uterine cancer, or other malignancies with an expected curative outcome.
- •7. Brain metastases that are either untreated, progressive or require any type of therapy (e.g., radiation, surgery, or steroids) to control symptoms from brain metastases within
- •60 days prior to the first study treatment dose.
- •8. Radiotherapy for the treatment of locally advanced disease or for metastatic sites of disease performed within 14 days prior to study enrollment, and/or radiation of > 30% of marrowbearing bone.
- •9. Symptomatic hypercalcemia requiring use of bisphosphonate therapy within 21 days prior to the first study treatment. Patients who receive bisphosphonate therapy specifically to
- •prevent skeletal events and who do not have a history of clinically significant hypercalcemia are eligible.
- •10. Current peripheral neuropathy Grade = 2 per NCI-CTCAE version 4.0.
- •11. History of exposure to the following cumulative doses of anthracyclines as specified below.
- •o Doxorubicin > 500 mg/m2 o Liposomal doxorubicin > 900 mg/m2 o Epirubucin > 720 mg/m2 o Mitoxantrone > 120 mg/m2
- •o Idarubicin > 90 mg/m2 If another anthracycline or more than one anthracycline has been used, then the cumulative dose must not exceed the equivalent of 500 mg/m2 doxorubicin.
- •13. Cardiopulmonary dysfunction as defined by: - Uncontrolled hypertension (systolic >150 mm Hg and/or diastolic > 100 mm Hg)
- •- Inadequately controlled angina or serious cardiac arrhythmia not controlled by adequate medication
- •o Inadequate left ventricular ejection function (LVEF) at baseline, as defined as LVEF <50% by either
- •echocardiogram or MUGA o History of symptomatic congestive heart failure (CHF – Grade = 3 per NCI CTCAE version 4.0 or Class = II New York Health Association (NYHA criteria o History of a decrease in LVEF to <40% or symptomatic CHF with prior trastuzumab treatment o Myocardial infarction within 6 months prior to randomization
- •o Current dyspnoea at rest due to complications of advanced malignancy, or other disease requiring continuous oxygen therapy
- •General exclusion criteria:
- •14. Current severe, uncontrolled systemic disease (e.g. clinically significant cardiovascular, pulmonary or metabolic disease; wound healing disorders; ulcers; bone fractures).
- •15. Current pregnancy and lactation.
- •16. Major surgical procedure or significant traumatic injury within approximately 28 days prior to randomization or anticipation of the need for major surgery during the course of study treatment. Et al.
研究者
相似试验
未知
3 期
Phase III clinical trial of RG3502 and RG1273 for breast cancer patientsPatients who have HER2 -positive (IHC 3+ and /or ISH+) progressive or recurrent locally advanced or previously untreated metastatic breast cancerJPRN-jRCT2080221448Chugai Pharmaceutical Co., Ltd.1,092
进行中（未招募）
1 期
A Study of Trastuzumab-DM1 Plus Pertuzumab Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer [MARIANNE] .First line treatment in HER2 positive progressive or recurrent locally advanced or metastatic breast cancer (MBC)MedDRA version: 18.0Level: PTClassification code 10065430Term: HER-2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0Level: PTClassification code 10006198Term: Breast cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-017905-13-SEF. Hoffmann-La Roche Ltd1,092
进行中（未招募）
1 期
A Study of Trastuzumab-DM1 Plus Pertuzumab Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer [MARIANNE] .EUCTR2009-017905-13-BEF. Hoffmann-La Roche Ltd1,095
进行中（未招募）
1 期
A randomized, 3 arm, multicentre, phase III study to evaluate the efficacy and the safety of T-DM1 combined with pertuzumab or T-DM1 combined with pertuzumab-placebo (blinded for pertuzumab), versus the combination of trastuzumab plus taxane, as first line treatment in HER2- positive progressive or recurrent locally advanced or metastatic breast cancer (MBC). - MARIANNEFirst line treatment in HER2 positive progressive or recurrent locally advanced or metastatic breast cancer (MBC)MedDRA version: 18.0Level: PTClassification code 10065430Term: HER-2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0Level: PTClassification code 10006198Term: Breast cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-017905-13-HUF. Hoffmann-La Roche Ltd1,095
进行中（未招募）
1 期
A Study of Trastuzumab-DM1 Plus Pertuzumab Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer [MARIANNE] .First line treatment in HER2 positive progressive or recurrent locally advanced or metastatic breast cancer (MBC)MedDRA version: 19.0Level: PTClassification code 10065430Term: HER-2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: PTClassification code 10006198Term: Breast cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-017905-13-PTF. Hoffmann-La Roche Ltd1,092